Movement disorders in patients with schizophrenia and a history of substance abuse

被引:5
|
作者
Hansen, Lars K. [1 ]
Nausheen, Bina [1 ,2 ]
Hart, Deborah [1 ]
Kingdon, David [1 ,2 ]
机构
[1] Southern Hlth NHS Fdn Trust, Southampton, Hants, England
[2] Univ Southampton, Southampton, Hants, England
关键词
alcohol; schizophrenia; substance abuse; akathisia; extrapyramidal side effects; movement disorder; TARDIVE-DYSKINESIA; EXTRAPYRAMIDAL SYMPTOMS; RISK-FACTOR; AKATHISIA; CLINICIAN; SCALE; ONSET;
D O I
10.1002/hup.2305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective The movement disorders acute dystonia, akathisia, Parkinsonian symptoms and tardive dyskinesia [extrapyramidal side effects (EPSs)] are recognized adverse effects of antipsychotic medication. Previous studies have indicated that substance abuse in patients with schizophrenia can worsen EPS. This study therefore investigated the relationship between drug and alcohol use and EPS in a group of patients with schizophrenia. Methods Seventy patients with schizophrenia assessed for drug and alcohol use, global functioning, EPS and suicidality. Chlorpromazine equivalents were correlated to levels of EPS and substance abuse. Results Current EPS were found in 65% of the sample despite three-quarters of the patients receiving second-generation antipsychotics. An even higher level of patients, 87%, was found to have a history of EPS. A long history of schizophrenia independently predicted presence of any EPS, particularly akathisia, controlling for history of substance abuse which was a non-significant predictor. Conclusions History or current use of alcohol or drug abuse did not predict EPS, except for alcohol abuse at the time of diagnosis which was associated with current akathisia. Length of illness was correlated with EPS, whereas suicidality was not linked to akathisia. Neither chlorpromazine equivalent antipsychotic dose nor whether the patient received first-generation or second-generation antipsychotic medication was significantly associated with EPS or substance abuse. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:192 / 197
页数:6
相关论文
共 50 条
  • [1] Treatment of patients with schizophrenia and substance abuse disorders
    Tsuang, J
    Fong, TW
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (18) : 2249 - 2261
  • [2] Substance Abuse and Movement Disorders
    Brust, John C. M.
    [J]. MOVEMENT DISORDERS, 2010, 25 (13) : 2010 - 2020
  • [3] Movement disorders and substance abuse
    Lopez, W
    Jeste, DV
    [J]. PSYCHIATRIC SERVICES, 1997, 48 (05) : 634 - 636
  • [4] Psychosocial Treatment of Patients With Schizophrenia and Substance Abuse Disorders
    Tsuang, John
    Fong, Timothy W.
    Lesser, Ira
    [J]. ADDICTIVE DISORDERS & THEIR TREATMENT, 2006, 5 (02): : 53 - 66
  • [5] Pharmacological Treatment of Patients with Schizophrenia and Substance Abuse Disorders
    Tsuang, John
    Fong, Timothy W.
    Pi, Edmond
    [J]. ADDICTIVE DISORDERS & THEIR TREATMENT, 2005, 4 (04): : 127 - 137
  • [6] Atypical medications in schizophrenia patients with a history of substance abuse
    Scheller-Gilkey, G
    Woolwine, B
    Robinson, I
    Gay, O
    Miller, AH
    [J]. SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 213 - 214
  • [7] Group treatment of substance abuse for patients with schizophrenia or related disorders
    Cohen, D
    Tempier, R
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1999, 44 (09): : 928 - 928
  • [8] Use of atypical antipsychotics in schizophrenia patients with a history of substance abuse
    Scheller-Gilkey, G
    Woolwine, BJ
    Moynes, KA
    Kant, CA
    Robinson, IC
    Gay, O
    Miller, AH
    [J]. SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 244 - 244
  • [9] Motivational interviewing for patients with comorbid schizophrenia and substance abuse disorders:: A review
    Bechdolf, A
    Pohlmann, B
    Geyer, C
    Ferber, C
    Klosterkötter, J
    Gouzoulis-Mayfrank, E
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2005, 73 (12) : 728 - 735
  • [10] Pharmacotherapy of patients with schizophrenia and substance abuse
    Wobrock, Thomas
    Soyka, Michael
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (03) : 353 - 367